Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536276 | 0.84 | GRM5 (0.40) | GRM5 | |
| SCHEMBL8142754 | 0.82 | GRM5 (0.59) | GRM5GRM1PDK4GPR119ESR2 | |
| SCHEMBL19989696 | 0.81 | GRM5 (0.69) | GRM5GRM1PDK4GPR119ESR2 | |
| SCHEMBL14995149 | 0.79 | GRM5 (0.70) | GRM5GRM1PDK4GPR119ESR2 | |
| SCHEMBL9903364 | 0.78 | GRM5 (0.62) | GRM5GRM1PDK4 | |
| Hydrochloric Acid SCHEMBL5798994 | 0.78 | GRM5 (0.52) | GRM5GRM1CYP11B2PDK4GPR119 | |
| SCHEMBL941018 | 0.77 | GRM5 (0.61) | GRM5GRM1PDK4ESR2 | |
| SCHEMBL2893138 | 0.77 | GRM5 (0.63) | GRM5GRM1PDK4ESR2 | |
| SCHEMBL3348910 | 0.77 | GRM5 (0.66) | GRM5GRM1CYP11B2PDK4ESR2 | |
| SCHEMBL8142756 | 0.76 | GRM5 (0.62) | GRM5GRM1PDK4ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ERIKSSON ANDERS | 2009-12-03 | — | — | US | disclosed |
| EP-1732903-B1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| EP-1732903-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095362-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | MMP9, MMP3, MMP25 | GRM5 2004/4885GRM1 1683/4885CYP11B2 154/4885 |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | MMP3, MMP9, MMP25 | GRM5 1923/4885GRM1 1570/4885CYP11B2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.